Japanese Researchers Highlight Potential New Mesothelioma Treatments in Editorial, According to Surviving Mesothelioma

Share Article

An editorial by authors from Hyogo College of Medicine suggests there is reason for the mesothelioma community to be hopeful about two new cancer drugs.

Mesothelioma Drugs Are the Subject of New Article

Editorial Showcases Potential Mesothelioma Drugs

YS110 and the α1-adrenoceptor antagonist naftopidil...have been identified to have anti-mesothelioma activity...

The authors of the editorial in Expert Review of Anticancer Therapy say a monoclonal antibody and an alpha blocker have both shown potential as new therapeutic options for treatment-resistant malignant pleural mesothelioma. Surviving Mesothelioma has just published an article on their conclusions. Click here to read it now.

The three Japanese researchers focused on two new drugs that have both been the subject of promising mesothelioma research in recent years.

“The CD26-targeting monoclonal antibody YS110 and the α1-adrenoceptor antagonist naftopidil and its analogue have been identified to have anti-mesothelioma activity and are expected to be evaluated soon for clinical use in mesothelioma,” writes author Takashi Nakano.

The editorial goes on to summarize the research on YS110 and naftopidil and the impact it could have on mesothelioma patients.

“Surviving Mesothelioma has reported on both of these potential new therapies for mesothelioma in the past and we are encouraged to see that they are still being considered ‘promising’ by researchers who understand the extreme challenges of mesothelioma treatment,” says Alex Strauss, Managing Editor of Surviving Mesothelioma.

To read more about the current research on YS110 and naftopidil, see Editorial Showcases Potential New Pleural Mesothelioma Treatments, now available on the Surviving Mesothelioma website.

Takashi, N et al, “Possible new therapeutic agents for malignant pleural mesothelioma: anti-CD26 monoclonal antibody and naftopidil”, October 8, 2016, Expert Review of Anticancer Therapy, http://www.tandfonline.com/doi/full/10.1080/14737140.2016.1241150

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website